Discontinued — last reported Q4 '25
Products & Services · Intangible assets
Reblozyl — Intangible assets
Merck & Co. Reblozyl — Intangible assets decreased by 10.7% to $2.50B in Q4 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2023
Last reportedQ4 2025
Rolls up toIntangible assets — net
How to read this metric
An increase typically reflects additional capital investment or milestone payments for rights, while a decrease suggests ongoing amortization or potential impairment of the asset's value.
Detailed definition
This metric represents the carrying value of intangible assets specifically associated with the Reblozyl product line, p...
Peer comparison
Comparable to capitalized in-process research and development or acquired product rights reported by other pharmaceutical companies under their specific therapeutic portfolios.
Metric ID:
mrk_segment_reblozyl_intangible_assetsHistorical Data
3 periods
| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $3.20B | $2.80B | $2.50B |
| QoQ Change | — | -12.5% | -10.7% |
| YoY Change | — | -12.5% | -10.7% |
Range$2.50B – $3.20B
Avg YoY Growth-11.6%
Median YoY Growth-11.6%
Current Streak2+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s reblozyl — intangible assets?
- Merck & Co. (MRK) reported reblozyl — intangible assets of $2.50B in Q4 2025.
- What does reblozyl — intangible assets mean?
- The recorded accounting value of the intellectual property and licensing rights owned by the company for the Reblozyl drug product.